<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1624">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03635879</url>
  </required_header>
  <id_info>
    <org_study_id>AX-18-018_PK</org_study_id>
    <nct_id>NCT03635879</nct_id>
  </id_info>
  <brief_title>Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain Triglycerides</brief_title>
  <official_title>A Phase 1, Single-Center, Pilot, Single-Dose, 6-Way Crossover Study to Compare Six Formulations of Medium Chain Triglycerides on the Pharmacokinetics of Ketone Body Production</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerecin</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerecin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, open label, randomized, 6-way crossover, pilot PK study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      12 healthy, male subjects enrolled, subject will be randomized to receive a single dose of&#xD;
      one of six treatment, with a 2 day washout in between each dosing period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study redesign&#xD;
  </why_stopped>
  <start_date type="Anticipated">February 13, 2019</start_date>
  <completion_date type="Anticipated">April 16, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 16, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total ketones</measure>
    <time_frame>1 day</time_frame>
    <description>Area Under the Curve (AUC) AUC 0 - last</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total ketones</measure>
    <time_frame>1 day</time_frame>
    <description>AUC 0 - 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total ketones</measure>
    <time_frame>1 day</time_frame>
    <description>AUC 0 - 6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total ketones</measure>
    <time_frame>1 day</time_frame>
    <description>AUC 0 - 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total ketones</measure>
    <time_frame>1 day</time_frame>
    <description>Maximum Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>B-hydroxybutyrate</measure>
    <time_frame>1 day</time_frame>
    <description>AUC 0 - last</description>
  </primary_outcome>
  <primary_outcome>
    <measure>B-hydroxybutyrate</measure>
    <time_frame>1 day</time_frame>
    <description>AUC 0 - 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>B-hydroxybutyrate</measure>
    <time_frame>1 day</time_frame>
    <description>AUC 0 - 6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>B-hydroxybutyrate</measure>
    <time_frame>1 day</time_frame>
    <description>AUC 0 - 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>B-hydroxybutyrate</measure>
    <time_frame>1 day</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acetoacetate</measure>
    <time_frame>1 day</time_frame>
    <description>AUC 0 - last</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acetoacetate</measure>
    <time_frame>1 day</time_frame>
    <description>AUC 0 - 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acetoacetate</measure>
    <time_frame>1 day</time_frame>
    <description>AUC 0 - 6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acetoacetate</measure>
    <time_frame>1 day</time_frame>
    <description>AUC 0 - 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acetoacetate</measure>
    <time_frame>1 day</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>MCTprocal medical food</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitaflo MCTprocal, single dose (20 g MCT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Milk/tricaprilin oil blend</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lactose-free milk and tricaprilin oil, blended,single dose (20 g tricaprilin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC-1207</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AC-1207 liquid, single dose (20 g tricaprilin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC-1205</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AC-1205 liquid, single dose (20 g tricaprilin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC-1206</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AC-1206 liquid, single dose (20 g tricaprilin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC-1202</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AC-1206 liquid, single dose (20 g tricaprilin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MCTprocal medical food</intervention_name>
    <description>32 g MCTprocal (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1</description>
    <arm_group_label>MCTprocal medical food</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Milk/tricaprilin oil blend</intervention_name>
    <description>154 mL of lactose-free skim milk/21 mL of tricaprilin oil blended and then mixed in 180 mL of water at Hour 0 Day 1</description>
    <arm_group_label>Milk/tricaprilin oil blend</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AC-1207</intervention_name>
    <description>AC-1207 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1</description>
    <arm_group_label>AC-1207</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AC-1205</intervention_name>
    <description>AC-1205 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1</description>
    <arm_group_label>AC-1205</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AC-1206</intervention_name>
    <description>AC-1206 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1</description>
    <arm_group_label>AC-1206</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-1202</intervention_name>
    <description>AC-1202 (20 g MCT) mixed in 240 mL of water at Hour 0 Day 1</description>
    <arm_group_label>AC-1202</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy, adult, male 18 55 years of age, inclusive, at Screening.&#xD;
&#xD;
          2. Continuous non smoker who has not used nicotine containing products for at least 3&#xD;
             months prior to Day -1 of Period 1 and throughout the study based on self-reporting.&#xD;
&#xD;
          3. Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at Screening.&#xD;
&#xD;
          4. Medically healthy with no clinically significant medical history, physical&#xD;
             examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or&#xD;
             designee. At screening, subjects must have alanine aminotransferase (ALT), aspartate&#xD;
             aminotransferase (AST) and alkaline phosphatase (ALP) ≤ the upper limit of normal and&#xD;
             triglyceride levels must be &lt; 250 mg/dL.&#xD;
&#xD;
          5. Hemoglobin levels ≥ the lower limit of normal at Screening and Day -1 of Period 1.&#xD;
&#xD;
          6. A non vasectomized subject must agree to use a condom with spermicide or abstain from&#xD;
             sexual intercourse during the study. (No restrictions are required for a vasectomized&#xD;
             male provided his vasectomy has been performed 4 months or more prior to Day -1 of&#xD;
             Period 1. A subject who has been vasectomized less than 4 months prior to Day -1 of&#xD;
             Period 1 must follow the same restrictions as a non vasectomized male).&#xD;
&#xD;
          7. Understands the study procedures in the informed consent form (ICF), and be willing&#xD;
             and able to comply with the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is mentally or legally incapacitated or has significant emotional problems at&#xD;
             the time of the screening visit or expected during the conduct of the study.&#xD;
&#xD;
          2. History or presence of clinically significant medical or psychiatric condition or&#xD;
             disease in the opinion of the PI or designee.&#xD;
&#xD;
          3. History of any illness that, in the opinion of the PI or designee, might confound the&#xD;
             results of the study or poses an additional risk to the subject by their participation&#xD;
             in the study.&#xD;
&#xD;
          4. History or presence of alcoholism or drug abuse within the past year prior to Day -1&#xD;
             of Period 1.&#xD;
&#xD;
          5. History or presence of galactosemia or hypersensitivity or idiosyncratic reaction to&#xD;
             the study drugs, related compounds, milk, palm or coconut oil, or soy.&#xD;
&#xD;
          6. History or presence of symptomatic diverticular disease, uncontrolled gastroesophageal&#xD;
             reflux disease, ulcers, inflammatory bowel disease, irritable bowel syndrome or&#xD;
             recurrent diarrhea, or gout.&#xD;
&#xD;
          7. Positive urine drug results at Screening or Check-in.&#xD;
&#xD;
          8. Positive alcohol results at Screening or Check-in. One repeat assessment is permitted.&#xD;
&#xD;
          9. Positive results at Screening for human immunodeficiency virus (HIV), hepatitis B&#xD;
             surface antigen (HBsAg), or hepatitis C virus (HCV).&#xD;
&#xD;
         10. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at&#xD;
             Screening. One repeat assessment is permitted.&#xD;
&#xD;
         11. Seated heart rate is lower than 40 bpm or higher than 99 bpm at Screening.&#xD;
&#xD;
         12. QTcF interval is &gt;460 msec or subject has ECG findings deemed abnormal with clinical&#xD;
             significance by the PI or designee at Screening.&#xD;
&#xD;
         13. Estimated creatinine clearance ≤ 80 mL/min at Screening.&#xD;
&#xD;
         14. Unable to refrain from or anticipates the use of any drug, including prescription and&#xD;
             non-prescription medications, herbal remedies, or vitamin supplements beginning 14&#xD;
             days prior to Day -1 of Period 1 and throughout the study. Acetaminophen (up to 2 g&#xD;
             per 24 hours) may be permitted during the study.&#xD;
&#xD;
         15. Has been on a diet incompatible with the on-study diet, in the opinion of the PI or&#xD;
             designee, within the 28 days prior to Day -1 of Period 1 and throughout the study.&#xD;
&#xD;
         16. Has been following a ketogenic diet, in the opinion of the PI or designee, within 2&#xD;
             weeks prior to Day -1 of Period 1.&#xD;
&#xD;
         17. Is lactose intolerant.&#xD;
&#xD;
         18. Is unable to complete the standard breakfast prior to dosing on Day 1 of each Period.&#xD;
&#xD;
         19. Donation of blood or significant blood loss within 56 days prior to Day -1 of Period&#xD;
             1.&#xD;
&#xD;
         20. Plasma donation within 7 days prior to Day -1 of Period 1.&#xD;
&#xD;
         21. Participation in another clinical study within 28 days prior to Day -1 of Period 1.&#xD;
             The 28-day window will be derived from the date of the last blood collection or&#xD;
             dosing, whichever is later, in the previous study to Day -1 of Period 1 of the current&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>September 25, 2018</last_update_submitted>
  <last_update_submitted_qc>September 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

